M&A Deal Summary |
|
---|---|
Date | 2011-04-14 |
Target | Clinical Data |
Sector | Medical Products |
Buyer(s) | Forest Laboratories |
Deal Type | Add-on Acquisition |
Deal Value | 1.2B USD |
Advisor(s) | J.P. Morgan Securities (Financial) Cooley (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1956 |
Sector | Medical Products |
Employees | 5,800 |
Revenue | 3.1B USD (2013) |
Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe.
DEAL STATS | # |
---|---|
Overall | 2 of 4 |
Sector (Medical Products) | 1 of 2 |
Type (Add-on Acquisition) | 2 of 4 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 2 of 3 |
Year (2011) | 1 of 1 |
Size (of disclosed) | 2 of 4 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2007-01-01 |
Cerexa
Oakland, California, United States Cerexa, Inc. was a privately held specialty pharmaceutical company, created as a spin-out from the sale of Peninsula Pharmaceuticals to Johnson & Johnson, focused on developing and commercializing novel anti-infective therapies for the treatment of life-threatening infections. |
Buy | $480M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-01-08 |
Aptalis Pharma
Mont-Saint-Hilaire, Quebec, Canada Aptalis is a leading multinational specialty pharmaceutical company. The Company develops and markets a broad line of prescription products used to treat gastrointestinal diseases and disorders. |
Buy | $2.9B |